Background Epidemiological evidence proposes the direct involvement of the liver enzymes in atrial fibrillation. These relationships are controversial and mechanistically unclear. As part of the British Regional Heart Study, we investigated whether change in liver enzymes over time associates with atrial fibrillation in men initially free of this heart condition.
Introduction
The direct involvement of liver enzymes in cardiovascular disease, especially gamma-glutamyl transferase (GGT) [1] , remains controversial [2, 3] . Recent population-based evidence suggests that circulating liver enzymes also associates independently with atrial fibrillation (AF) [4] [5] [6] [7] . The evidence on this finding is limited, inconsistent and mechanistically unclear. In the Framingham cohort, associations existed between AF risk and alanine transaminase (ALT) and aspartate transaminase (AST) [6] , while in the Atherosclerosis Risk in Communities study, GGT but not ALT or AST predicted new-onset AF [7] . These studies mostly accounted for baseline characteristics of participants initially free of AF, rendering it difficult to capture and account for the evolving pathophysiology. Heart failure contributes to atrial dysfunction and vice versa [8] [9] [10] [11] , but also increases central and hepatic venous pressure leading to congestive hepatopathy, augmenting circulating GGT, bilirubin and alkaline phosphatase (ALP) levels [12] [13] [14] . However, the relationship between AF and liver enzymes could be more complex as the association also exists in the absence of clinically diagnosed heart failure [6] . Currently, no evidence is available on the change in liver enzymes over time and newonset AF. With the incidence of AF projected to more than [15] , an understanding of the mechanisms at work has clinical importance. To investigate the relationship between new-onset AF and change in liver enzymes over time, we used prospective data from the British Regional Heart Study.
Materials and methods
Reporting of this study conforms to STROBE statement [16] .
Study population
The British Regional Heart Study is a prospective cohort study involving 7735 randomly selected men from 24 towns representing all major British regions (response rate, 78%) [17] . We followed the men since 1978-1980 when they were aged 40-59 years and re-examined them at ages 60-79 years (1998) (1999) (2000) and 71-92 years (2010-2012). The first re-examination after 20 years included 4252 men (77% response rate) and the second after 32 years 1722 men (55% response rate). For the present investigation, we used the first re-examination as baseline (1998) (1999) (2000) and the second (2010-2012) as the follow-up for outcome assessment. All participants gave informed written consent and could withdraw at any stage. The protocol complied with the Declaration of Helsinki of 1975 (as revised in 1983) and all relevant local research ethics committees provided ethical approval.
Participant examinations and exclusions
The re-examinations included completion of a questionnaire on lifestyle and medical history, a physical examination, a 12-lead electrocardiogram (ECG) and collection of fasting blood samples using the Sarstedt Monovette system for biochemical analysis.
Electrocardiograms were recorded using a Siemens Sicard 460 and transmitted to the University of Glasgow ECG core laboratory for analysis using the University of Glasgow ECG interpretation programme [18] with an additional model for automated Minnesota coding [19] . All reports were carefully reviewed and edited wherever necessary. Prevalent heart failure at baseline and follow-up was based on a doctor-confirmed diagnosis of heart failure from medical records and verified by review of available clinical information from primary and secondary care records.
Blood samples were frozen and stored at À20°C on the day of collection and transferred in batches for storage at À70°C until analysis, which was carried out after no more than one freeze-thaw cycle. Details of measurement and classification methods for smoking status, alcohol intake, blood pressure and blood lipids in this cohort have previously been described [20] [21] [22] . C-reactive protein (CRP) was assayed by ultrasensitive nephelometry (Dade Behring, Milton Keynes, UK) and plasma glucose by a glucose oxidase method using a Falcor-600 automated analyser. Hepatic enzymes including GGT, AST, ALT and ALP, as well as serum albumin, total protein and total bilirubin, were measured using a Hitachi 747 automated analyser. The normal laboratory range was 8-61 U/L for GGT, < 37 U/L for AST, < 41 U/L for ALT and 35-129 U/L for ALP. The measurement of baseline and follow-up liver enzymes followed the same enzymatic calorimetric assay principle [23] [24] [25] . N-terminal prohormone of brain natriuretic peptide (NTproBNP) was measured using the Elecsys 2010 electrochemiluminescence method (Roche Diagnostics, Burgess Hill, UK).
Statistical analysis
For database management and statistical analysis, we used SAS software, version 9.4 (SAS Institute Inc., Cary, NC, USA). The distributions of GGT, ALT, AST, ALP, blood glucose, NTproBNP and C-reactive protein were normalised by logarithmic transformation. We compared means and proportions by the standard normal z-test and the v 2 statistic, while longitudinal changes in means and proportions were assessed by the PROC MIXED procedure and McNemar's test, respectively. Statistical significance was set at a level of 0Á05 on two-sided tests. We analysed associations with AF using logistic regression analysis to calculate odds ratios (OR) standardised to one standard deviation (SD) and 95% confidence intervals (CI), while allowing for covariates and potential confounders. We applied the forward stepwise procedure with P values for explanatory variables to enter and stay in the model set at 0Á05. Covariates included in the model were respective baseline liver enzymes, baseline age, body mass index, systolic blood pressure, total cholesterol, serum glucose, physical activity, smoking, drinking, use of antihypertensive medication and follow-up time. Physical activity used in the regression models was classified into inactive, occasional, light, moderate and vigorous; smoking into never, former and current smokers; and drinking into none, occasional, light, moderate and heavy drinkers. We performed sensitivity analysis by additionally, but separately, adjusting for baseline C-reactive protein, ALT, AST, ALT/AST ratio, bilirubin, NT-proBNP and their respective change (Δ). We also repeated our analysis after excluding participants with GGT outside its reference range (> 61 U/L), and those who had a previous myocardial infarction or heart failure at baseline or follow-up. Lastly, as NT-proBNP levels above 900 pg/mL in people aged 50-75 years is indicative of heart failure [26, 27] , we repeated our analysis in participants who had NT-proBNP levels below 900 pg/mL at both baseline and follow-up.
Results

Participant characteristics
We based our study on 1722 men who took part in both the first and second follow-up examinations. We excluded 256 participants without blood measurements at baseline or followup, 20 with no electrocardiogram measurements at follow-up, and 18 with AF at baseline, leaving 1428 participants for inclusion in the analysis. After a mean follow-up of 12Á3 years (5th to 95th percentile interval, 12Á1-12Á9 years), 108 new cases of AF were identified. The baseline characteristics of participants who developed or did not develop AF are presented in Table 1 and follow-up characteristics in Table S1 . Circulating levels of AST, ALT and ALP at baseline (P ≥ 0Á083) and followup (P ≥ 0Á054) did not differ between men who did or did not develop AF ( Figure S1 ). GGT was also similar in both groups at baseline (P = 0Á93), however GGT at follow-up (P < 0Á0001, Fig. 1a ) and change (Δ) in GGT from baseline to follow-up (+6Á12 vs. À2Á60 U/L, P = 0Á036) were higher in the men with AF at follow-up. In addition, both NT-proBNP (P < 0Á0001, Fig. 1b ) and total bilirubin (P < 0Á0001, Fig. 1c ) at follow-up were higher in the AF group and increased more markedly from baseline to follow-up (both P < 0Á0001), while mean Table 1 Baseline characteristics of men with and without atrial fibrillation (AF) at follow-up
With AF (n = 108) P
Drinking, n (%) Physically inactive, n (%) 66 (5Á0) 6 (5Á6) 0Á80
Previous myocardial infarction, n (%) 117 (8Á9) 10 (9Á3) 0Á70
Heart failure, n (%) 11 (0Á8) 1 (0Á9) 0Á86
Antihypertensive meds, n (%) 305 (23Á4)
(30Á6) 0Á092
Values are number of subjects (%), arithmetic mean AE SD or geometric mean (5th to 95th percentile interval). ALT, alanine transaminase; AST, aspartate transaminase; NT-proBNP, N-terminal prohormone of brain natriuretic peptide.
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haemoglobin did not differ between the groups at both baseline (P = 0Á82) and follow-up (P = 0Á74, Fig. 1d ). Self-reported alcohol intake did not differ between the groups at baseline (P = 0Á55) or follow-up (P = 0Á62) and intake declined from baseline to follow-up in both the AF (P = 0Á028) and non-AF groups (P < 0Á0001; data not shown). Similarly, the AST/ALT ratio as a measure of alcoholic liver damage did not differ between the groups at baseline (P = 0Á18) or follow-up (P = 0Á21) and decreased in both groups from baseline to follow-up (with AF, P < 0Á0001; without AF, P < 0Á0001; data not shown).
Univariate and multivariate analyses
In univariate analysis in the total group (Table S2) , ΔNT-proBNP correlated with ΔGGT (r = 0Á14, P < 0Á0001), Δtotal bilirubin (r = 0Á13, P < 0Á0001) and ΔALP (r = 0Á10, P = 0Á0001), but not with ΔALT (r = 0Á01, P = 0Á61) or ΔAST (r = 0Á04, P = 0Á17).
In univariate logistic regression analysis (Table 2) , none of the liver enzymes at baseline, or the change in AST, ALT or ALP was associated with AF. However, a 1-SD increase in ΔGGT was associated with a 21Á7% (95% CI, 5Á2-40Á6%; P = 0Á008) increased odds of developing AF. After adjusting for baseline GGT and other covariates and potential confounders (Table 2) , the above association between AF and ΔGGT remained significant (OR, 1Á18; 95% CI, 1Á01-1Á37; P = 0Á032).
Associations with AST, ALT and ALP (P ≥ 0Á14) or their change (P ≥ 0Á73) remained nonsignificant.
Sensitivity analysis
Additional adjustments (Table 3) for baseline C-reactive protein as a marker of inflammation (P = 0Á018), ALT (P = 0Á032), AST (P = 0Á031), the AST/ALT ratio to account for alcoholic liver disease (P = 0Á032), ALP (P = 0Á032) as well as their respective change from baseline to follow-up (P ≤ 0Á032) did not appreciably affect our findings. Our results also remained significant after excluding those with GGT levels outside the reference range (> 61 U/L, P = 0Á0004), those with a previous myocardial infarction (P = 0Á032), and even after excluding 74 participants with prevalent and incident heart failure (P = 0Á015). However, when accounting for baseline (P = 0Á088) or change in NT-proBNP (P = 0Á40) as a clinical measure of heart failure and left ventricular systolic-and diastolic dysfunction, the relationship between AF risk and ΔGGT was no longer present. When adjusting for Δtotal bilirubin, statistical significance was also lost (P = 0Á13). Entering both ΔNT-proBNP and Δtotal bilirubin in the model confirmed the absence of an independent relationship between AF and ΔGGT (P = 0Á62). Lastly, by repeating our analysis in participants with NT-proBNP levels below 900 pg/mL at both baseline and follow-up, the relationship between AF and ΔGGT was absent (OR, 0Á86; 95% CI, 0Á55-1Á33; P = 0Á50). 
Discussion
We investigated in a representative sample of older British men initially free of AF, whether change in liver enzymes over 12Á3 years were associated with new-onset AF. While no evidence existed for baseline liver enzymes, initial findings indicated a seemingly robust association between AF and change in GGT after multiple adjustments and exclusions including participants with prevalent and incident heart failure. However, this relationship was dependent on the progression of heart failure as represented by change in NT-proBNP. The concept of cardiovascular events, and more recently AF relating to liver enzymes has become a matter of debate and remains mechanistically unclear [1] [2] [3] [4] [5] [6] [7] . Sinner et al. [6] followed 3744 participants (mean age, 65 years) free of AF and heart failure at baseline and found a respective 19% and 12% increased risk of developing new-onset AF per one standard deviation increase in baseline ALT and AST. The authors confirmed these results after multiple adjustments including interim heart failure as a dichotomous variable, but not for AST after adjusting for C-reactive protein as a marker of systemic inflammation [6] . They provided no descriptive data on interim heart failure and incidence was likely higher in the AF group that was older by a mean of 6Á8 years [6] . In our study population of similar age, no such evidence existed for the liver transaminases, even in univariate analysis and including participants with incident heart failure. Alonso et al. [7] provided the first prospective evidence for linking new-onset AF with GGT, but were unable to confirm a relationship with ALT or AST in 9333 men and women aged 53-75 years. This study involved extreme-case statistical analysis by quintiles of baseline GGT. The authors did include baseline NT-proBNP and C-reactive protein in the quintile analysis and confirmed the results after excluding participants with prevalent heart failure at baseline. However, there was no indication whether NT-proBNP was included in the continuous analysis when mentioning a 20% increased risk of AF per doubling of GGT [7] .
The above studies were limited in their ability to capture the pathophysiological progression of disease by accounting only for baseline covariates and potential confounders. We were able to show in those who developed AF, that a greater increase in GGT was paralleled by NT-proBNP and bilirubin as respective sensitive markers of progressive heart failure [28] and congestive hepatopathy [29] . In heart failure patients, elevated liver function tests are a consequence of either backward failure, increasing central venous pressure or forward failure with attenuated cardiac output and consequent liver perfusion [12] [13] [14] 30] . Decreased liver perfusion elevates the transaminases due to hepatocellular damage [14, 29, 31] , while increased central venous pressure transmits to the hepatic veins and results in elevations in GGT, bilirubin and ALP [32, 33] . In our study, GGT and bilirubin, which did not differ at baseline between the groups, were higher in those with AF at follow-up, while ALP was borderline higher in the AF group at baseline and followup. ALP is normally elevated in more extreme cholestatic conditions [34] , and it is reasonable to assume that the effects of hepatic congestion would firstly be seen for GGT and bilirubin before the impediment to bile flow. Van Deursen et al. [14] reported that abnormalities in all liver function tests were associated with invasively measured central venous pressure. Importantly, higher central venous pressure was predominantly related to GGT and bilirubin [14] . From our results, it Table 2 Associations between atrial fibrillation and baseline liver enzyme concentrations and changes in liver enzyme concentrations between baseline and follow-up
Main independent variables
Atrial fibrillation (odds ratio, 95%CI) Unadjusted +Age Primary model
Primary model included baseline gamma-glutamyl transferase, age, body mass index, systolic blood pressure, diastolic blood pressure, total cholesterol, serum glucose, physical activity, smoking, drinking, use of antihypertensive medication and follow-up time.
*
, P < 0Á05; † , P < 0Á01. Δ denotes delta or change from baseline to follow-up.
seems more likely that the backward failure-central venous pressure mechanism could explain our findings, especially as the liver transaminases did not differ between those with and without AF. In addition, the positive univariate associations in the total group of NT-proBNP with ΔGGT, ΔALP and Δtotal bilirubin, but not with ΔALT or ΔAST, at least in part, support this pathway.
The link between AF and ΔGGT was dependent on ΔNT-proBNP, even in the absence of diagnosed heart failure, therefore capturing the confounding effect of heart failure at subclinical level. Supporting this was the absence of the AF-ΔGGT link when repeating our analysis in participants who consistently had NT-proBNP levels below 900 ng/mL (above which is indicative of heart failure for people aged 50-75 years) [26, 27] . Heart failure and AF often coincide with causal pathways in both directions [8] [9] [10] [11] . This is at least partly supported by our results confirming the known [35, 36] relationship between NT-proBNP and AF (OR, 1Á53; 95% CI, 1Á24-1Á88; P < 0Á0001) in fully adjusted models which also included ΔGGT and Δtotal bilirubin. On balance, the link between the failing heart and the liver described above also seems evident with the disappearance of the association between AF and GGT after adjusting for Δtotal bilirubin as both GGT and bilirubin are elevated in congestive hepatopathy [12] [13] [14] . Taken together, no direct relationship seems apparent between AF and the liver enzymes, which, even in the absence of prevalent and incident heart failure, seems due to progression of heart failure leading to both AF and hepatic congestion.
The current study must be interpreted within the context of its potential limitations. Although our cohort is socially representative of older white British men, our results may not be generalisable to younger populations, women and other ethnicities. We investigated overall AF only and therefore cannot comment on the associations of the liver enzymes and AF type (i.e., valvular, paroxysmal, persistent or permanent). The increase in total bilirubin from baseline to follow-up could also be due to augmented bilirubin production (increased haemolysis) [37] ; however, this seems unlikely as haemoglobin levels did not differ between those with and without AF at both baseline and follow-up. Although the same enzymatic calorimetric assay principle was used to determine the liver enzyme levels at baseline and follow-up, the storage time difference of samples could have affected the results. However, a similar trend in GGT levels could be seen in participants who passed away after 1998-2000 (not included in the present study) with GGT being higher in those with AF compared to those without ( Figure S2 ).
In conclusion, the direct relationship between atrial fibrillation and liver enzymes is absent and depends, at least in part, on the progression of heart failure as captured by NT-proBNP. + baseline CRP 1Á20 (1Á03-1Á40) 0Á018
+ ΔCRP 1Á20 (1Á03-1Á39) 0Á020
+ baseline ALT 1Á18 (1Á01-1Á37) 0Á032
+ ΔALT 1Á18 (1Á01-1Á37) 0Á032
+ baseline AST 1Á18 (1Á01-1Á37) 0Á032
+ ΔAST 1Á18 (1Á02-1Á38) 0Á031
+baseline ALP 1Á18 (1Á01-1Á37) 0Á032
+ ΔALP 1Á18 (1Á01-1Á37) 0Á032
+ AST/ALT ratio 1Á18 (1Á01-1Á37) 0Á032
+ ΔAST/ALT ratio 1Á18 (1Á02-1Á38) 0Á031
+ exclude GGT > 61 U/L 1Á44 (1Á18-1Á76) 0Á0004
+ exclude previous MI 1Á18 (1Á01-1Á37) 0Á032
+ exclude HF 1Á21 (1Á04-1Á42) 0Á015
+ Baseline bilirubin 1Á18 (1Á01-1Á37) 0Á032
+ Δbilirubin 1Á13 (0Á97-1Á32) 0Á13
+ Baseline NT-proBNP 1Á15 (0Á98-1Á34) 0Á088
+ ΔNT-proBNP 1Á08 (0Á91-1Á28) 0Á40
+ ΔNT-proBNP + Δbilirubin 1Á05 (0Á88-1Á25) 0Á62
The primary model included baseline gamma-glutamyl transferase, age, body mass index, systolic blood pressure, diastolic blood pressure, total cholesterol, serum glucose, physical activity, smoking, drinking, use of antihypertensive medication and follow-up time. ALT, alanine transaminase; AST, aspartate transaminase; CRP, C-reactive protein; GGT, gamma-glutamyl transferase; HF, heart failure; MI, myocardial infarction; NT-proBNP, Nterminal prohormone of brain natriuretic peptide. Δ denotes delta or change from baseline to follow-up.
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